Company / EPS (Diluted)
Cartesian Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$4.49
FY2025
5-year range
-$49.76 / -$0.22
FY2021-FY2025
Trend
+91.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $-0.22 to $-4.49 over the past 2 years.
Based on SEC 10-K filings.
-4.49 in FY2025.
Declined from $-0.22 to $-4.49 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) increased 91.0% year-over-year.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.49 | +91.0% |
| FY2024 | -$49.76 | -22518.2% |
| FY2023 | -$0.22 | +67.6% |
| FY2022 | -$0.68 | +44.3% |
| FY2021 | -$1.22 | +58.2% |
| FY2020 | -$2.92 | +8.8% |
| FY2019 | -$3.20 | +59.2% |
| FY2016 | -$7.84 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026